Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Enterprise Value (2020 - 2022)

Atea Pharmaceuticals has reported Enterprise Value over the past 3 years, most recently at -$665.0 million for Q3 2022.

  • Quarterly results put Enterprise Value at -$665.0 million for Q3 2022, up 20.8% from a year ago — trailing twelve months through Sep 2022 was -$665.0 million (up 20.8% YoY), and the annual figure for FY2021 was -$764.4 million, up 10.09%.
  • Enterprise Value for Q3 2022 was -$665.0 million at Atea Pharmaceuticals, up from -$684.5 million in the prior quarter.
  • Over the last five years, Enterprise Value for AVIR hit a ceiling of -$17.1 million in Q1 2020 and a floor of -$850.1 million in Q4 2020.
  • Median Enterprise Value over the past 3 years was -$705.5 million (2022), compared with a mean of -$581.6 million.
  • Biggest five-year swings in Enterprise Value: tumbled 4762.37% in 2021 and later grew 20.8% in 2022.
  • Atea Pharmaceuticals' Enterprise Value stood at -$850.1 million in 2020, then grew by 10.09% to -$764.4 million in 2021, then rose by 13.0% to -$665.0 million in 2022.
  • The last three reported values for Enterprise Value were -$665.0 million (Q3 2022), -$684.5 million (Q2 2022), and -$705.5 million (Q1 2022) per Business Quant data.